Pfizer's New Anti-Smoking Drug May Be a Big Winner (PFE)

Includes: GSK, PFE
by: Mick Weinstein

Excerpt from our One Page Annotated Wall Street Journal Summary (get it e-mailed to you every morning by signing up here):

Drug Shows Promise Helping Smokers Quit

  • Summary: A new Pfizer (NYSE:PFE) drug called Chantix (brand name for varenicline) seems to be particularly effective in helping smokers quit. Research published in JAMA this week indicates that Chantix is more effective than GlaxoSmithKline's (NYSE:GSK) popular Zyban and Wellbutrin. The drug, unlike nicotine patches, actually blocks nicotine's ability to attach to the body, so the user no longer gets the buzz from smoking. Some question the objectivity of the studies however, since the majority of the authors had some type of financial relationship with Pfizer, including consulting contracts.
  • Comment on related stocks/ETFs: Follow Pfizer? See recent articles on its sale of its OTC unit to J&J (Eddy Elfenbein calls both companies winners), and its new generic Zoloft.